We are live on ! Find out more
PCM

Penserra Capital Management Portfolio holdings

AUM $8.52B
1-Year Est. Return 37.76%
This Fund
S&P 500
This Quarter Est. Return
+16.8%
1 Year Est. Return
+37.76%
3 Year Est. Return
+116.32%
5 Year Est. Return
+122.1%
10 Year Est. Return
+1,892.45%
AUM
$2.63B
AUM Growth
+$690M
Cap. Flow
+$451M
Cap. Flow %
17.16%
Top 10 Hldgs %
21.75%
Holding
1,066
New
264
Increased
497
Reduced
181
Closed
122

Top Buys

Rank Stock Value
1
BABA icon
Alibaba
BABA
+$21.1M
2
MTCH icon
Match Group
MTCH
+$16.7M
3
AMZN icon
Amazon
AMZN
+$15.3M
4
MELI icon
Mercado Libre
MELI
+$13.9M
5
PDD icon
Pinduoduo
PDD
+$13.6M

Top Sells

Rank Stock Value
1
BBBY
Bed Bath & Beyond
BBBY
+$16M
2
PPLI
People Inc
PPLI
+$7.82M
3
ZM icon
Zoom
ZM
+$7.6M
4
KLAC icon
KLA
KLAC
+$7.1M
5
WUBA
58.com Inc
WUBA
+$6.96M

Sector Composition

Rank Sector Weight
1 Consumer Discretionary 35.11%
2 Technology 20.8%
3 Communication Services 14.79%
4 Industrials 4.05%
5 Financials 3.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
JT
876
DELISTED
Jianpu Technology Inc. American Depositary Shares, each representing twenty Class A Ordinary Shares
JT
$4K ﹤0.01%
1,191
-2,324
-66% -$11.2K
AERI
877
DELISTED
Aerie Pharmaceuticals
AERI
$4K ﹤0.01%
+396
New +$4.82K
RDUS
878
DELISTED
Radius Health, Inc.
RDUS
$4K ﹤0.01%
+396
New +$4.89K
FLXN
879
DELISTED
Flexion Therapeutics, Inc.
FLXN
$4K ﹤0.01%
+420
New +$5.15K
AKBA icon
880
Akebia Therapeutics
AKBA
$252M
$3K ﹤0.01%
+1,220
New +$10.7K
ANAB icon
881
AnaptysBio
ANAB
$1.68B
$3K ﹤0.01%
+232
New +$4.19K
ARDX icon
882
Ardelyx
ARDX
$997M
$3K ﹤0.01%
+760
New +$4.57K
AUTL
883
Autolus Therapeutics
AUTL
$562M
$3K ﹤0.01%
+284
New +$4.12K
ENR icon
884
Energizer
ENR
$1.55B
$3K ﹤0.01%
102
+12
+13% +$550
FCFS icon
885
FirstCash
FCFS
$8.78B
$3K ﹤0.01%
68
+8
+13% +$489
MNKD icon
886
MannKind Corp
MNKD
$1.32B
$3K ﹤0.01%
+1,954
New +$3.38K
PBYI icon
887
Puma Biotechnology
PBYI
$454M
$3K ﹤0.01%
+338
New +$3.44K
PRTA icon
888
Prothena Corp
PRTA
$450M
$3K ﹤0.01%
+338
New +$4.07K
RIGL icon
889
Rigel Pharmaceuticals
RIGL
$750M
$3K ﹤0.01%
+144
New +$3.54K
TXMD icon
890
TherapeuticsMD
TXMD
$24M
$3K ﹤0.01%
+47
New +$3.75K
URGN icon
891
UroGen Pharma
URGN
$2.29B
$3K ﹤0.01%
+190
New +$4.3K
VYGR icon
892
Voyager Therapeutics
VYGR
$201M
$3K ﹤0.01%
+320
New +$3.76K
SYRS
893
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$3K ﹤0.01%
+39
New +$4.43K
GTHX
894
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$3K ﹤0.01%
+324
New +$5.35K
BCEL
895
DELISTED
Atreca, Inc. Class A Common Stock
BCEL
$3K ﹤0.01%
+250
New +$3.73K
RUBY
896
DELISTED
Rubius Therapeutics, Inc
RUBY
$3K ﹤0.01%
+690
New +$3.65K
TCDA
897
DELISTED
Tricida, Inc. Common Stock
TCDA
$3K ﹤0.01%
+428
New +$6.25K
PDLI
898
DELISTED
PDL BioPharma, Inc.
PDLI
$3K ﹤0.01%
+974
New +$3.11K
BDSI
899
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$3K ﹤0.01%
+858
New +$3.65K
ACIU icon
900
AC Immune
ACIU
$240M
$2K ﹤0.01%
+608
New +$4.36K
34 35
36
37 38

Similar funds

GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NB
Norinchukin Bank Tokyo, Japan $8.57B AUM 20.17% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
ACM
Advisors Capital Management Ridgewood, New Jersey $8.58B AUM 23.43% 1-Year Est. Return
FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return
AAF
Andra AP-fonden Goteborg, Sweden $8.39B AUM 21.19% 1-Year Est. Return

Penserra Capital Management's Q3 2020 Portfolio in Review

As of Q3 2020, Penserra Capital Management held 1,066 positions worth $2.63B, up 36% from $1.94B the previous quarter. Its ten largest holdings account for 22% of the portfolio.

Penserra Capital Management deployed $451M of net new capital in Q3 2020, opening 264 new positions and adding to 497 existing holdings. Its largest new stake was Match Group: 157,606 shares worth $17.4M.

By sector, the portfolio is most concentrated in Consumer Discretionary at 35% of assets, up from 29% a quarter earlier, followed by Technology and Communication Services.

On the sell side, the largest reduction was Bed Bath & Beyond, an estimated $16M trimmed.

  • Penserra Capital Management's largest Q3 2020 buy was Match Group: 157,606 shares worth $17.4M.
  • Penserra Capital Management added most to Alibaba in Q3 2020, an estimated $21.1M increase.
  • Penserra Capital Management's biggest Q3 2020 reduction was Bed Bath & Beyond, cutting an estimated $16M.
  • Penserra Capital Management fully exited 58.com Inc in Q3 2020, selling an estimated $6.96M.
  • Penserra Capital Management's ten largest holdings make up 22% of its $2.63B portfolio in Q3 2020.
  • Penserra Capital Management opened 264 new positions and closed 122 in Q3 2020.
  • Penserra Capital Management's portfolio value rose 36% quarter-over-quarter to $2.63B.

Based on Penserra Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.